Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: A comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2174-2180

  Dziadziuszko, Rafal ^a   Merrick, Daniel T ^a   Witta, Samir E ^a   Mendoza, Adelita D ^a   Szostakiewicz, Barbara ^a   Szymanowska, Amelia ^a   Rzyman, Witold ^a   Dziadziuszko, Katarzyna ^a   Jassem, Jacek ^a   Bunn Jr , Paul A ^a   Varella Garcia, Marileila ^a   Hirsch, Fred R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; SOMATOMEDIN C RECEPTOR; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRISOMY; ADENOCARCINOMA; ANEUPLOIDY; CANCER STAGING; CHEMISTRY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG SURGERY; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PULMONARY SURGICAL PROCEDURES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 77952309862     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.6611     Document Type: Article

References (29)

1. Jemal A, Thun MJ, Ries LA, et al: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672-1694, 2008
2. Chitnis MM, Yuen JS, Protheroe AS, et al: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:6364-6370, 2008
3. Dziadziuszko R, Camidge DR, Hirsch FR: The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 3:815-818, 2008
4. Haluska P, Shaw HM, Batzel GN, et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007 (Pubitemid 47583908)
5. Rodon J, Patnaik A, Stein M, et al: A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist antibody, in patients with advanced solid tumors. J Clin Oncol 25:160s, 2007 (suppl; abstr 3590)
6. Tolcher AW, Rothenberg ML, Rodon J, et al: A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 25:118s, 2007 (suppl; abstr 3002)
7. Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516-2522, 2009
8. Morgillo F, Woo JK, Kim ES, et al: Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66:10100-10111, 2006 (Pubitemid 44672064)
9. Jones HE, Goddard L, Gee JM, et al: Insulinlike growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814, 2004 (Pubitemid 40065552)
10. Knowlden JM, Jones HE, Barrow D, et al: Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signaling: Implication for gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 111:79-91, 2008 (Pubitemid 352009232)
11. Morgillo F, Kim WY, Kim ES, et al: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13:2795-2803, 2007 (Pubitemid 46788049)
12. Dziadziuszko R, Witta SE, Cappuzzo F, et al: Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12:3078-3084, 2006 (Pubitemid 43837354)
13. Hirsch FR, Herbst RS, Olsen C, et al: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351-3357, 2008
14. Hirsch FR, Dziadziuszko R, Thatcher N, et al: Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 112:1114-1121, 2008 (Pubitemid 351304597)
15. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol 24:5034-5042, 2006 (Pubitemid 46631407)
16. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714, 2007 (Pubitemid 47357522)
17. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005 (Pubitemid 40812628)
18. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
19. Hosmer DW, Lemeshow S: Regression models for survival data, in Hosmer DW, Lemeshow S (eds): Applied Survival Analysis. New York, NY, John Willey and Sons Inc, 1999, pp 87-112
20. Thorpe SM, Rose C, Rasmussen BB, et al: Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47:6126-6133, 1987 (Pubitemid 18018765)
21. Huang F, Greer A, Hurlburt W, et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170, 2009
22. Cappuzzo F, Toschi L, Tallini G, et al: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17:1120-1127, 2006 (Pubitemid 43985248)
23. Merrick DT, Dziadziuszko R, Szostakiewicz B, et al: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 25:397s, 2007 (suppl; abstr 7550)
24. Ludovini V, Bellezza G, Pistola L, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842-849, 2009
25. Nakamura H, Kawasaki N, Taguchi M, et al: Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: A meta-analysis. Thorax 61:140-145, 2006 (Pubitemid 43235431)
26. Defize LH, Boonstra J, Meisenhelder J, et al: Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 109:2495-2507, 1989 (Pubitemid 19282633)
27. Hirsch FR, Varella-Garcia M, Bunn PA, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003 (Pubitemid 46606235)
28. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
29. Nahta R, Yuan LX, Zhang B, et al: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128, 2005 (Pubitemid 41713383)